


# NKF ADVISES EQT FUTURE ON ITS INVESTMENT IN SHL MEDICAL

*Posted on 14 December 2022*



**Category:** [Deal & transactions](#)

**Tags:** [Benedikt Hadorn](#), [Daniela Lötscher](#), [EQT](#), [Janine Reudt-Demont](#), [Katalin Siklosi](#), [Niederer Kraft Frey](#), [NKF](#), [Philip Spoerlé](#), [Shl Medical](#), [Slider](#)



**Niederer Kraft Frey** has advised **EQT Future Fund** on the acquisition of EQT VIII's participation in **SHL Medical**, a provider of advanced drug delivery solutions. Roger Samuelsson, SHL Medical's founder, will remain the majority shareholder. Milbank acted as lead counsel on this transaction.

SHL Medical is a global solutions provider in the design, development, and manufacturing of advanced delivery devices such as auto injectors, pen injectors, and innovative specialty delivery systems for large-volume and high viscosity formulations. The company is a pioneer in medical autoinjectors, which allow patients to safely self-administer medications at home while reducing the burden on healthcare systems.

EQT first partnered with SHL Medical in January 2020 through EQT VIII fund. EQT Future with ATHOS and other co-investors will now support SHL Medical in its next phase of growth and in expanding its production footprint to the United States and Europe.

The **NKF** team was led by corporate/m&a partner **Philip Spoerlé** (pictured), working with senior associate **Katalin Siklosi** and associate **Benedikt Hadorn** (both corporate/m&a), counsel **Janine Reudt-Demont** (IP/IT), as well as associate **Daniela Lötscher** (employment).